Trial · NCT03818607
Results by group298
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 298
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| LDH Level at Week 27 (Parallel Comparison) | ABP 959 | 205.69 | 95% Confidence Interval 191.23 to 221.24 | U/L | |
| LDH Level at Week 27 (Parallel Comparison) | Eculizumab | 193.53 | 95% Confidence Interval 180.80 to 207.17 | U/L | |
| Time-adjusted Area Under the Effect Curve (AUEC) of LDH (Crossover Comparison Per Assigned Treatment) | ABP 959 | 1445.76 | 95% Confidence Interval 1295.63 to 1613.28 | U*day/L/week | |
| Time-adjusted Area Under the Effect Curve (AUEC) of LDH (Crossover Comparison Per Assigned Treatment) | Eculizumab | 1473.44 | 95% Confidence Interval 1321.86 to 1642.41 | U*day/L/week | |
| Mean Total Complement (50% Total Hemolytic Complement Activity [CH50]) | ABP 959/Eculizumab | Baseline | 6.4 | Standard Deviation 13.48 | Percent of LLN for all CH50 values |
| Mean Total Complement (50% Total Hemolytic Complement Activity [CH50]) | Eculizumab/ABP 959 | Baseline | 2.6 | Standard Deviation 4.11 | Percent of LLN for all CH50 values |
| Mean Total Complement (50% Total Hemolytic Complement Activity [CH50]) | ABP 959/Eculizumab | Week 27 | 7.5 | Standard Deviation 16.68 | Percent of LLN for all CH50 values |
| Mean Total Complement (50% Total Hemolytic Complement Activity [CH50]) | Eculizumab/ABP 959 | Week 27 | 6.3 | Standard Deviation 12.25 | Percent of LLN for all CH50 values |
| Mean Total Complement (50% Total Hemolytic Complement Activity [CH50]) | ABP 959/Eculizumab | Week 39 | 7.4 | Standard Deviation 23.80 | Percent of LLN for all CH50 values |
| Mean Total Complement (50% Total Hemolytic Complement Activity [CH50]) | Eculizumab/ABP 959 | Week 39 | 5.1 | Standard Deviation 10.36 | Percent of LLN for all CH50 values |
| Mean Total Complement (50% Total Hemolytic Complement Activity [CH50]) | ABP 959/Eculizumab | Week 53 | 12.0 | Standard Deviation 34.29 | Percent of LLN for all CH50 values |
| Mean Total Complement (50% Total Hemolytic Complement Activity [CH50]) | Eculizumab/ABP 959 | Week 53 | 4.6 | Standard Deviation 6.84 | Percent of LLN for all CH50 values |
| Mean Total Complement (50% Total Hemolytic Complement Activity [CH50]) | ABP 959/Eculizumab | Week 65 | 25.6 | Standard Deviation 65.27 | Percent of LLN for all CH50 values |
| Mean Total Complement (50% Total Hemolytic Complement Activity [CH50]) | Eculizumab/ABP 959 | Week 65 | 7.8 | Standard Deviation 11.37 | Percent of LLN for all CH50 values |
| Mean Total Complement (50% Total Hemolytic Complement Activity [CH50]) | ABP 959/Eculizumab | Week 79 | 15.8 | Standard Deviation 35.65 | Percent of LLN for all CH50 values |
| Mean Total Complement (50% Total Hemolytic Complement Activity [CH50]) | Eculizumab/ABP 959 | Week 79 | 6.5 | Standard Deviation 12.67 | Percent of LLN for all CH50 values |
| Mean Total Hemoglobin Levels | ABP 959/Eculizumab | Baseline | 113.0 | Standard Deviation 15.03 | g/L |
| Mean Total Hemoglobin Levels | Eculizumab/ABP 959 | Baseline | 113.8 | Standard Deviation 16.09 | g/L |
| Mean Total Hemoglobin Levels | ABP 959/Eculizumab | Week 27 | 110.6 | Standard Deviation 15.19 | g/L |
| Mean Total Hemoglobin Levels | Eculizumab/ABP 959 | Week 27 | 116.1 | Standard Deviation 16.08 | g/L |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03818607/results